We and others have demonstrated that blocking the GLP1RA-induced GFRAL→CGRPelPBN pathway with another incretin, glucose-dependent insulinotropic polypeptide, removes the aversive element of treatment without reversing the anorexia19,25, which has important implications in the development of obesity drugs. The gene discussed is GCG; the disease is obesity disorder.